BOSTON--(BUSINESS WIRE)--Feb. 21, 2019--
Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
Lloyd Carney has been appointed to its board of directors as an
independent director. Mr. Carney is a prominent technology executive
with experience leading innovative, high-growth organizations. He
currently serves as the Chairman and Chief Executive Officer of ChaSerg
Technology Acquisition Corp., a technology acquisition company. The
addition of Mr. Carney brings Vertex’s board of directors to 10 members.
“We are thrilled to have Lloyd join the Vertex Board. His wealth of
leadership and management experience paired with his passion for
technology and innovation bring an invaluable perspective to the Vertex
leadership team,” said Jeffrey Leiden, M.D., Ph.D., Chairman, President
and Chief Executive Officer of Vertex.
“It’s an honor to join an organization with a strong track record of
discovering new medicines to treat life-threatening diseases like cystic
fibrosis,” said Lloyd Carney. “I look forward to working with my fellow
board members to support Vertex in its continued efforts to serially
innovate for the benefit of people with serious diseases.”
Prior to his role atChaSerg, Mr. Carney served as Chief
Executive Officer of Brocade Communications Systems, a global supplier
of networking hardware and software, until its acquisition by Broadcom
in 2017. Previously, Mr. Carney served as Chief Executive Officer of
Xsigo Systems, a cloud-based infrastructure solutions provider, until
its acquisition by Oracle. He has also served as the Chief Executive
Officer and Chairman of Micromuse Inc., a software solutions provider
for business and service assurance. Earlier in his career he held senior
leadership roles at Juniper Networks Inc., Nortel Networks Inc., and Bay
Networks Inc. Mr. Carney currently serves as an independent director of
Visa Inc. and the chairman of the board of Nuance Communications Inc.
Mr. Carney holds a Bachelor of Science degree in electrical engineering
technology from Wentworth Institute, a Master of Science degree in
applied business management from Lesley College, and an honorary
doctorate degree in engineering from Wentworth Institute.
About Vertex
Vertex is a global biotechnology company that invests in scientific
innovation to create transformative medicines for people with serious
and life-threatening diseases. In addition to clinical development
programs in CF, Vertex has more than a dozen ongoing research programs
focused on the underlying mechanisms of other serious diseases.
Founded in 1989 in Cambridge, Mass., Vertex's headquarters is now
located in Boston'sInnovation District. Today, the company has research
and development sites and commercial offices in the United States,
Europe, Canada, Australia and Latin America. Vertex is consistently
recognized as one of the industry's top places to work, including being
named to Science magazine's Top Employers in the life sciences ranking
for nine years in a row.
For additional information and the latest updates from the company,
please visit www.vrtx.com.
(VRTX-GEN)
View source version on businesswire.com: https://www.businesswire.com/news/home/20190221005847/en/
Source: Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Investors:
Michael
Partridge, 617-341-6108
or
Eric Rojas, 617-961-7205
or
Zach
Barber, 617-341-6470
or
Media:
mediainfo@vrtx.com
or
North
America: +1 617-341-6992
